

DOI: 10.29289/259453942018V28S1052

## EVALUATION OF PATIENTS WITH INVASIVE BREAST CARCINOMA SUBMITTED TO NEOADJUVANT CHEMOTHERAPY ATTENDED AT DR ARNALDO VIEIRA DE CARVALHO CANCER INSTITUTE FORM 2006 TO 2012

Fábio F. O. Rodrigues<sup>1</sup>, Etiénne A. Bastos<sup>1</sup>, Laís A. Inaba<sup>1</sup>, Eveline A. Silva<sup>1</sup>, Rodrigo M. Silva<sup>1</sup>, Carlos E. Fristachi<sup>1</sup>

<sup>1</sup>Instituto do Câncer Doutor Arnaldo Vieira de Carvalho – São Paulo (SP), Brazil.

**Objectives:** Evaluate the characteristics of patients with invasive breast carcinoma submitted to neoadjuvant chemotherapy attended at Dr Arnaldo Vieira de Carvalho Cancer Institute form 2006 to 2012. **Methods:** A longitudinal study was performed, descriptive type, retrospective, of patients with invasive breast carcinoma attended at ICAVC in Sao Paulo; data were analyzed on the data base of Microsoft Excel@. **Results:** Were evaluated 267 patients, of wich, 48 (18%) underwent adjuvant chemotherapy with predominance of patients with tumors T3 (35.4%), DCI (91.6%) and luminal (54.1%); the main regimen used was anthracycline in association with taxane (45.8%); 14.5% patients presented complete clinical-pathological response (pCR); 74.5% underwent conservative surgery; 5.4% presented local recurrence and 23.6% presented distant metastasis in the mean period of 2 years (disease-free survival), the overall survival was 10 years. **Conclusion:** Neoadjuvant chemotherapy was shown in this study as a treatment of choice in locally advanced tumors targeting pCR with increased conservative breast surgeries.